Amyloid beta 1-42 inhibits entorhinal cortex activity in the beta-gamma range: Role of GSK-3

Current Alzheimer Research

Volumn 9, Issue 7, 2012, Pages 857-863

  Peña Ortega, Fernando ^a,b   Solis Cisneros, Ángeles ^a   Ordaz, Benito ^a,b   Balleza Tapia, Hugo ^a   López Guerrero, Juan Javier ^b  

^a INSTITUTO DE NEUROBIOLOGÍA   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Alzheimer's disease; Amyloid beta protein; Gamma oscillations; GSK 3; Lithium; Network activity

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; AMYLOID BETA PROTEIN[1-42]; GLYCOGEN SYNTHASE KINASE 3; LITHIUM; MAGNESIUM ION;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENTORHINAL CORTEX; IN VITRO STUDY; MOUSE; NONHUMAN; OSCILLATION; PRIORITY JOURNAL; RAT;

AMYLOID BETA-PEPTIDES; ANIMALS; ENTORHINAL CORTEX; GLYCOGEN SYNTHASE KINASE 3; NEURONS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RATS; RATS, WISTAR; SYNAPTIC POTENTIALS;

EID: 84866671516     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512802455403     Document Type: Article

References (65)

1. Chrobak JJ, Buzsáki, G. Gamma oscillations in the entorhinal cortexof the freely behaving. rat J Neurosci 18: 388-398 (1998).
2. Penley SC, Hinman JR, Sabolek HR, Escabí MA, Markus EJ, Chrobak JJ. Theta and gamma coherence across the septotemporalaxis during distinct behavioral states. Hippocampus (in press)(2011).
3. Coben LA, Danziger WL, Berg L. Frequency analysis of the restingawake EEG in mild senile dementia of Alzheimer type Electroencephalogr. Clin Neurophysiol 55: 372-380 (1983).
4. Coben LA, Danziger W, Storandt M. A longitudinal EEG study ofmild senile dementia of Alzheimer type, changes at 1 year and at25 years. Electroencephalogr Clin Neurophysiol 61: 101-112(1985).
5. Schreiter-Gasser U, Gasser T, Ziegler P. Quantitative EEG analysisin early onset Alzheimer's disease, correlations with severity, clinicalcharacteristics, visual EEG and CCT Electroencephalogr. ClinNeurophysiol 90: 267-272 (1994).
6. Dierks T, Frölich L, Ihl R, Maurer K. Correlation between cognitivebrain function and electrical brain activity in dementia of Alzheimertype. J Neural Transm Gen Sect 99: 55-62 (1995).
7. Claus JJ, Kwa VI, Teunisse S, Walstra GJ, van Gool WA, KoelmanJH, et al. Slowing on quantitative spectral EEG is a marker for rateof subsequent cognitive and functional decline in early Alzheimerdisease. Alzheimer Dis Assoc Disord 12: 167-174 (1998).
8. Yoshimura M, Isotani T, Yagyu T, Irisawa S, Yoshida T, SugiyamaM, et al. Global approach to multichannel electroencephalogramanalysis for diagnosis and clinical evaluation in mild Alzheimer'sdisease. Neuropsychobiology 49: 163-166 (2004).
9. Kowalski JW, Gawel M, Pfeffer A, Barcikowska M. The diagnosticvalue of EEG in Alzheimer disease, correlation with the severityof mental impairment. J Clin Neurophysiol 18: 570-575 (2001).
10. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synapticchange in Alzheimer's disease. Am J Pathol 155: 853-8562(1999).
11. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, GreengardP, et al. Correlation between elevated levels of amyloid betapeptidein the brain and cognitive decline. JAMA 283: 1571-1577(2000).
12. Driver JE, Racca C, Cunningham MO, Towers SK, Davies CH, Whittington MA, et al. Impairment of hippocampal gammafrequencyoscillations in vitro in mice overexpressing human amyloidprecursor protein (APP). Eur J Neurosci 26: 1280-1288 (2007).
13. Hermann D, Both, M, Ebert, U, Gross G, Schoemaker H, DraguhnA, et al. Synaptic transmission is impaired prior to plaque formationin amyloid precursor protein-overexpressing mice without alteringbehaviorally-correlated sharp wave-ripple complexes. Neuroscience162: 1081-1090 (2009).
14. Brown JT, Teriakidis A, Randall AD. A pharmacological investigationof the role of GLUK5-containing receptors in kainate-drivenhippocampal gamma band oscillations. Neuropharmacology 50:47-56 (2006).
15. Pálhalmi J, Paulsen O, Freund TF, Hájos, N. Distinct properties ofcarbachol-and DHPG-induced network oscillations in hippocampalslices. Neuropharmacology 47: 381-9 (2004).
16. Adaya-Villanueva A, Ordaz B, Balleza-Tapia H, Márquez-RamosA, Peña-Ortega F. Beta-like hippocampal network activity is differentiallyaffected by amyloid beta peptides. Peptides 31: 1761-6(2010).
17. Peña F, Ordaz B, Balleza-Tapia H, Bernal-Pedraza R, Márquez-Ramos A, Carmona-Aparicio L, Giordano M. Beta-amyloid protein(25-35) disrupts hippocampal network activity, role of Fyn-kinase. Hippocampus 20: 78-96 (2010).
18. Balleza-Tapia H, Huanosta-Gutiérrez A, Márquez-Ramos A, AriasN, Peña F. Amyloid β oligomers decrease hippocampal spontaneousnetwork activity in an age-dependent manner. Curr AlzheimerRes 7: 453-462 (2010).
19. Balleza-Tapia H, Peña F. Pharmacology of the intracellular pathwaysactivated by amyloid beta protein. Mini Rev Med Chem 9:724-740 (2009).
20. Giese KP. GSK-3: a key player in neurodegeneration and memoryIUBMB Life 61:516-21 (2009).
21. Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3betain Alzheimer's disease and accumulation in argyrophilic grains andin neurones at different stages of neurofibrillary degeneration. NeuropatholAppl Neurobiol 33: 43-55 (2007).
22. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I. Distribution levels and activity of glycogen synthase kinase-3 inthe Alzheimer disease brain. J Neuropathol Exp Neurol 56: 70-78(1997).
23. Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, Imahori K. Preferential labeling of Alzheimer neurofibrillary tangleswith antisera for tau protein kinase (TPK) I/glycogen synthasekinase-3 beta and cyclin-dependent kinase 5: a component of TPKII. Acta Neuropathol 92: 232-241 (1996).
24. Mateo I, Infante J, Llorca J, Rodríguez E, Berciano J, CombarrosO. Association between glycogen synthase kinase-3beta geneticpolymorphism and late-onset Alzheimer's disease. Dement GeriatrCogn Disord 21: 228-232 (2006).
25. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, RoseJB, et al. Neuroprotective effects of regulators of the glycogen synthasekinase-3beta signaling pathway in a transgenic model of Alzheimer'sdisease are associated with reduced amyloid precursorprotein phosphorylation. J Neurosci 27: 1981-191 (1996).
26. Hu S, Begum AN, Jones MR, Oh MS, Beech WK, Beech BH, et al. GSK3 inhibitors show benefits in an Alzheimer's disease (AD)model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 33: 193-206 (2009).
27. Serenó L, Coma M, Rodríguez M, Sánchez-Ferrer P, Sánchez MB, Gich I, et al. A novel GSK-3beta inhibitor reduces Alzheimer's pathologyand rescues neuronal loss in vivo. Neurobiol Dis 35: 359-367 (2009).
28. Fiorentini A, Rosi MC, Grossi C, Luccarini I, Casamenti, F. Lithiumimproves hippocampal neurogenesis, neuropathology and cognitivefunctions in APP mutant mice. PLoS One 5: e14382 (2010).
29. Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, etal. Dysregulation of the mTOR pathway mediates impairment ofsynaptic plasticity in a mouse model of Alzheimer's disease. PLoSOne 5: e12845 (2010).
30. Jo J, Whitcomb DJ, Olsen KM, Kerrigan TL, Lo SC, Bru-MercierG, et al. Aβ(1-42) inhibition of LTP is mediated by a signalingpathway involving caspase-3: Akt1 and GSK-3β. Nat Neurosci 14:545-547 (2011).
31. Li S, Hong S, Shepardson NE, Walsh DM, Shanka GM, Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampallong-term depression by disrupting neuronal glutamate uptake. Neuron 62: 788-801 (2009).
32. Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, YoshidaN, et al. Spherical aggregates of beta-amyloid (amylospheroid)show high neurotoxicity and activate tau protein kinase I/glycogensynthase kinase-3beta. Proc Natl Acad Sci USA 100: 6370-6375(2003).
33. De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, et al. Alzheimer's disease-type neuronal tau hyperphosphorylationinduced by A beta oligomers. Neurobiol Aging 29:1334-1347 (2008).
34. Hernández F, Gómez de Barreda E, Fuster-Matanzo A, Lucas JJ, Avila J. GSK3: a possible link between beta amyloid peptide andtau protein. Exp Neurol 223: 322-325 (2010).
35. Colom LV, Castañeda MT, Bañuelos C, Puras G, García-Hernández A, Hernandez S, et al. Medial septal beta-amyloid 1-40injections alter septo-hippocampal anatomy and function. NeurobiolAging 31: 46-57 (2010).
36. Quiroz JA, Gould TD, Manji HK. Molecular effects of lithium. Mol Interv 4: 259-272 (2004).
37. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, LiosatosM, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl AcadSci USA 95: 6448-6453 (1998).
38. Flint AC, Maisch US, Kriegstein AR. Postnatal development oflow [Mg2+] oscillations in neocortex. J Neurophysiol 78: 1990-1996 (1997).
39. Flint AC, Connors BW. Two types of network oscillations in neocortexmediated by distinct glutamate receptor subtypes and neuronalpopulations. J Neurophysiol 75: 951-957 (1996).
40. Peña, F. PACAP modulates the respiratory rhythm generated in thebrainstem slice preparation. Adv Exp Med Biol 669: 119-122(2010).
41. Peña F, Alavez-Pérez N. Epileptiform activity induced by pharmacologicreduction of M-current in the developing hippocampus invitro. Epilepsia 47: 47-54 (2006).
42. Romcy-Pereira RN, de Araujo DB, Leite JP, Garcia-Cairasco N. Asemi-automated algorithm for studying neuronal oscillatory patterns, a wavelet-based timefrequency and coherence analysis. JNeurosci Methods 167: 384-392 (2008).
43. Otsu N. A threshold selection method from gray-level histograms. IEEE Trans Syst Man Cyber 9: 62-66 (1979).
44. Chauhan NB, Lichtor T, Siegel GJ. Aging potentiates Abetainduceddepletion of SNAP-25 in mouse hippocampus. Brain Res982: 219-227 (2003).
45. Nimmrich V, Grimm C, Draguhn A, Barghorn S, Lehmann A, Schoemaker H, et al. Amyloid beta oligomers (A beta(1-42) globulomer)suppress spontaneous synaptic activity by inhibition of P/Qtypecalcium currents. J Neurosci 28: 788-797 (2008).
46. Suh EC, Jung YJ, Kim YA, Park EM, Lee KE. A beta 25-35 inducespresynaptic changes in organotypic hippocampal slice cultures. Neurotoxicology 29(4): 691-699 (2008).
47. Zhu LQ, Liu D, Hu, J, Cheng J, Wang SH, Wang Q, Wang F, et al. GSK-3 beta inhibits presynaptic vesicle exocytosis by phosphorylatingP/Q-type calcium channel and interrupting SNARE complexformation. J Neurosci 30: 3624-3633 (2010).
48. Hooper C, Markevich V, Plattner F, Killick R, Schofield E, EngelT, Hernandez F, et al. Glycogen synthase kinase-3 inhibition is integralto long-term potentiation. Eur J Neurosci 25: 81-6 (2007).
49. Cai F, Wang F, Lin FK, Liu C, Ma LQ, Liu, J, et al. Redox modulationof long-term potentiation in the hippocampus via regulationof the glycogen synthase kinase-3beta pathway. Free Radic BiolMed 45: 964-970 (2008).
50. Zhu LQ, Wang SH, Liu D, Yin YY, Tian Q, Wang XC, et al. Activationof glycogen synthase kinase-3 inhibits long-term potentiationwith synapse-associated impairments. J Neurosci 27:12211-12220 (2007).
51. Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto ZA, Wang YT, Collingridge GL. The role of GSK-3 in synaptic plasticity. Br J Pharmacol 153(1): S428-37 (2008).
52. Villette V, Poindessous-Jazat F, Simon A, Léna C, Roullot E, Bellessort B, et al. Decreased rhythmic GABAergic septal activityand memory-associated theta oscillations after hippocampal amyloid-beta pathology in the rat. J Neurosci 30: 10991-11003 (2010).
53. Engel T, Goñi-Oliver P, Gómez de Barreda E, Lucas JJ, HernándezF, Avila J. Lithium, a potential protective drug in Alzheimer's disease. Neurodegener Dis 5: 247-249 (2008).
54. Leyhe T, Eschweiler GW, Stransky E, Gasser T, Annas P, BasunH, et al. Increase of BDNF serum concentration in lithium treatedpatients with early Alzheimer's disease. J Alzheimers Dis 16: 649-656 (2009).
55. Pomara N. Lithium treatment in Alzheimer's disease does not promotecognitive enhancement, but may exert long-term neuroprotectiveeffects. Psychopharmacology (Berl) 205: 169-170 (2009).
56. Medina M, Avila J. Glycogen synthase kinase-3 (GSK-3) inhibitorsfor the treatment of Alzheimer's disease. Curr Pharm Des 16: 2790-8 (2010).
57. Lauterbach EC, Victoroff J, Coburn KL, Shillcutt SD, Doonan SM, Mendez MF. Psychopharmacological neuroprotection in neurodegenerativedisease, assessing the preclinical data. J NeuropsychiatryClin Neurosci 22: 8-18 (2010).
58. Struve FA. Lithium-specific pathological electroencephalographicchanges, a successful replication of earlier investigative results. Clin Electroencephalogr 18: 46-53 (1987).
59. Opgenoorth E, Wolf R, Presslich O, Anderer P. Contralateral eyemovements and alpha reactivity of lithium patients in recognitiontasks. Pharmacopsychiatry 20: 208-212 (1987).
60. Harvey NS, Jarratt J, Ward NI. Trace elements and the electroencephalogramduring long-term lithium treatment. Br J Psychiatry160: 654-658 (1992).
61. Schulz C, Mavrogiorgou P, Schröter A, Hegerl U, Juckel G. Lithium-induced EEG changes in patients with affective disorders. Neuropsychobiology 42 (1): 33-7 (2000).
62. Terao T, Nakano, H, Inoue Y, Okamoto T, Nakamura J, Iwata N. Lithium and dementia, a preliminary study. Prog NeuropsychopharmacolBiol Psychiatry 30: 1125-1128 (2006).
63. Kessing LV, Søndergård L, Forman JL, Andersen PK. Lithiumtreatment and risk of dementia. Arch Gen Psychiatry 65(11): 1331-1335 (2008).
64. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer'sdisease in elderly patients with bipolar disorder. Br J Psychiatry190: 359-360 (2007).
65. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, GattazWF. Disease-modifying properties of long-term lithium treatmentfor amnestic mild cognitive impairment, randomised controlledtrial Br J Psychiatry 198: 351-356 (2011).